US 7,468,449 B2
Phenyl-furan compounds as vitamin D receptor modulators
Robert Peter Gajewski, Indianapolis, Ind. (US); Charles David Jones, Indianapolis, Ind. (US); Jianliang Lu, Fishers, Ind. (US); Tianwei Ma, Carmel, Ind. (US); Sunil Nagpal, Carmel, Ind. (US); and Ying Kwong Yee, Carmel, Ind. (US)
Assigned to Eli Lilly and Company, Indianapolis, Ind. (US)
Appl. No. 10/578,991
PCT Filed Nov. 16, 2004, PCT No. PCT/US2004/035527
§ 371(c)(1), (2), (4) Date May 11, 2006,
PCT Pub. No. WO2005/051936, PCT Pub. Date Jun. 09, 2005.
Claims priority of provisional application 60/524015, filed on Nov. 20, 2003.
Prior Publication US 2007/0105951 A1, May 10, 2007
Int. Cl. C07D 307/02 (2006.01); A61K 31/34 (2006.01)
U.S. Cl. 549—487  [514/471] 9 Claims
 
1. A compound represented by a formula below or a pharmaceutically acceptable salt derivative thereof:

OG Complex Work Unit Drawing
wherein;
R and R′ are independently C1-C4 alkyl;
RP, Rp′, and RF are independently selected from the group consisting of hydrogen and C1-C4 alkyl;
(L1) is oxygen;
(L2) is —C(R40)2—, where each R40 is independently hydrogen, C1-C5 alkyl or C1-C5 fluoroalkyl;
(L3) is —C(═X1) —, where X1 is O, S, CH2, or;
(LF) a bond;
ZF is

OG Complex Work Unit Drawing
where R4 and R5 are independent hydrogen, C1-C4 alkyl, —O—C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, —NH(C1-C4 alkyl), or cyclopropyl, with the proviso that only one of R4 or R5 may be hydrogen;
ZP is
methyl,
ethyl,
n-propyl,
1-methylethyl,
1-methylpropyl,
2-methylpropyl,
1,1-dimethylethyl,
1,1-dimethylpropyl,
1,2-dimethylpropyl, or
2,2-dimethylpropyl.